Celgene Corporation’s Trend Up, Especially After This Options Activity

 Celgene Corporation's Trend Up, Especially After This Options Activity

In today’s session Celgene Corporation (CELG) registered an unusually high (823) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the April, 2017 call, expecting serious CELG increase. With 823 contracts traded and 5804 open interest for the Apr, 17 contract, it seems this is a quite bullish bet. The option with symbol: CELG170421C00110000 closed last at: $5.95 or 56.6% up. About 1.38M shares traded hands. Celgene Corporation (NASDAQ:CELG) has risen 3.74% since March 29, 2016 and is uptrending. It has outperformed by 0.27% the S&P500.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on November, 3. They expect $1.31 EPS, up 16.96% or $0.19 from last year’s $1.12 per share. CELG’s profit will be $1.01 billion for 19.67 P/E if the $1.31 EPS becomes a reality. After $1.28 actual EPS reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 2.34% EPS growth.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Out of 20 analysts covering Celgene Corporation (NASDAQ:CELG), 17 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 85% are positive. $190 is the highest target while $83 is the lowest. The $137.29 average target is 33.17% above today’s ($103.09) stock price. Celgene Corporation has been the topic of 36 analyst reports since July 21, 2015 according to StockzIntelligence Inc. BTIG Research upgraded the stock to “Buy” rating in Thursday, August 4 report. The stock has “Outperform” rating given by RBC Capital Markets on Friday, January 29. The rating was initiated by Credit Suisse with “Outperform” on Wednesday, January 20. Standpoint Research initiated the stock with “Buy” rating in Thursday, January 14 report. On Wednesday, June 1 the stock rating was downgraded by BTIG Research to “Neutral”. SunTrust initiated Celgene Corporation (NASDAQ:CELG) on Thursday, January 7 with “Buy” rating. The rating was maintained by UBS with “Buy” on Friday, November 6. Suntrust Robinson initiated Celgene Corporation (NASDAQ:CELG) on Thursday, January 7 with “Buy” rating. JMP Securities maintained Celgene Corporation (NASDAQ:CELG) on Friday, July 24 with “Mkt Outperform” rating. On Wednesday, September 9 the stock rating was initiated by Jefferies with “Buy”.

According to Zacks Investment Research, “Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.”

Insitutional Activity: The institutional sentiment increased to 0.99 in 2016 Q2. Its up 0.06, from 0.93 in 2016Q1. The ratio improved, as 70 funds sold all Celgene Corporation shares owned while 411 reduced positions. 60 funds bought stakes while 418 increased positions. They now own 587.22 million shares or 5.24% less from 619.66 million shares in 2016Q1.
Moreover, Cornerstone Advisors has 0.17% invested in Celgene Corporation (NASDAQ:CELG) for 7,000 shares. Cibc Ww Markets Corporation has 0.13% invested in the company for 52,184 shares. Nomura Asset Mngmt Co Limited has 0.47% invested in the company for 255,567 shares. Murphy Capital Mngmt Inc last reported 0.48% of its portfolio in the stock. First Citizens Financial Bank accumulated 10,404 shares or 0.09% of the stock. Nippon Life holds 0.08% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 34,290 shares. Genesee Valley Trust Communication, a New York-based fund reported 12,520 shares. Baker Avenue Asset Limited Partnership last reported 0.05% of its portfolio in the stock. Thompson Davis And Incorporated accumulated 0.13% or 806 shares. Colony Gp Ltd Liability Co last reported 19,083 shares in the company. Sandy Spring National Bank last reported 0.26% of its portfolio in the stock. The Japan-based Mitsubishi Ufj Trust & Banking has invested 0.37% in Celgene Corporation (NASDAQ:CELG). Franklin Inc has 0.51% invested in the company for 9.55M shares. Main Street Research Limited Co accumulated 13,748 shares or 0.28% of the stock. Benin has 5,345 shares for 0.27% of their US portfolio.

Insider Transactions: Since July 28, 2016, the stock had 0 buys, and 7 insider sales for $29.76 million net activity. 20,000 shares were sold by BARKER RICHARD W, worth $2.22M. 27,500 Celgene Corporation (NASDAQ:CELG) shares with value of $3.14M were sold by LOUGHLIN JAMES J. KAPLAN GILLA sold $1.03M worth of stock. Another trade for 56,116 shares valued at $5.82 million was sold by Friedman Michael A. 43,134 shares with value of $4.92M were sold by CASEY MICHAEL D on Monday, August 22. $1.64 million worth of shares were sold by MARIO ERNEST on Friday, September 23. $11.00M worth of Celgene Corporation (NASDAQ:CELG) shares were sold by HUGIN ROBERT J.

Celgene Corporation is a biopharmaceutical company. The company has a market cap of $79.28 billion. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. It has a 39.07 P/E ratio. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin).

CELG Company Profile

Celgene Corporation (Celgene), incorporated on April 17, 1986, is a biopharmaceutical company. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Fool.com which released: “2 Reasons Celgene Corporation’s Future Just Got Brighter” on October 28, 2016, also Fool.com with their article: “Celgene Corporation Is Firing on All Cylinders” published on October 28, 2016, Nasdaq.com published: “Celgene Corporation Reveals 25% Rise In Q3 Bottom Line” on October 27, 2016. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Profitconfidential.com and their article: “Celgene Stock: THIS is Where Bulls Can Regain Footing in CELG Stock” published on October 21, 2016 as well as Businesswire.com‘s news article titled: “Celgene Corporation and Sage Bionetworks Announce Technology Collaboration to …” with publication date: October 18, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment